P10636 |
TAU_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10636 |
TAU_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P10636 |
TAU_HUMAN |
Mild neurocognitive disorder [ICD-11: 6D71] |
P10636 |
TAU_HUMAN |
Choreiform disorder [ICD-11: 8A01] |
P10636 |
TAU_HUMAN |
Parkinsonism [ICD-11: 8A00] |
P10636 |
TAU_HUMAN |
Central nervous system disease [ICD-11: 8A04-8D87] |
P10636 |
TAU_HUMAN |
Neurodegenerative disorder [ICD-11: 8A20-8A23] |
P11473 |
VDR_HUMAN |
Chronic kidney disease [ICD-11: GB61] |
P11473 |
VDR_HUMAN |
Hair/hair growth developmental defect [ICD-11: LC30] |
P11473 |
VDR_HUMAN |
Hyper-parathyroidism [ICD-11: 5A51] |
P11473 |
VDR_HUMAN |
Hypo-parathyroidism [ICD-11: 5A50] |
P11473 |
VDR_HUMAN |
Mineral deficiency [ICD-11: 5B5K] |
P11473 |
VDR_HUMAN |
Psoriasis [ICD-11: EA90] |
P11473 |
VDR_HUMAN |
Vitamin deficiency [ICD-11: 5B55-5B5F] |
P11473 |
VDR_HUMAN |
Low bone mass disorder [ICD-11: FB83] |
P11473 |
VDR_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P11473 |
VDR_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P11473 |
VDR_HUMAN |
Prostate disease [ICD-11: GA91] |
P11473 |
VDR_HUMAN |
Abnormal micturition [ICD-11: MF50] |
P11473 |
VDR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P11473 |
VDR_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
P11473 |
VDR_HUMAN |
Acne vulgaris [ICD-11: ED80] |
P84022 |
SMAD3_HUMAN |
Herpes simplex infection [ICD-11: 1F00] |
P84022 |
SMAD3_HUMAN |
Kidney fibrosis [ICD-11: GC01] |
Q03431 |
PTH1R_HUMAN |
Low bone mass disorder [ICD-11: FB83] |
Q03431 |
PTH1R_HUMAN |
Hypo-parathyroidism [ICD-11: 5A50] |
Q16236 |
NF2L2_HUMAN |
Ataxic disorder [ICD-11: 8A03] |
Q16236 |
NF2L2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 |
NF2L2_HUMAN |
Glaucoma [ICD-11: 9C61] |
Q16236 |
NF2L2_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q16236 |
NF2L2_HUMAN |
Macular degeneration [ICD-11: 9B75] |
Q16236 |
NF2L2_HUMAN |
Melanoma [ICD-11: 2C30] |
Q16236 |
NF2L2_HUMAN |
Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 |
NF2L2_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
Q16236 |
NF2L2_HUMAN |
Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 |
NF2L2_HUMAN |
Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 |
NF2L2_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 |
NF2L2_HUMAN |
Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 |
NF2L2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
Q16236 |
NF2L2_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P07550 |
ADRB2_HUMAN |
Glaucoma [ICD-11: 9C61] |
P07550 |
ADRB2_HUMAN |
Asthma [ICD-11: CA23] |
P07550 |
ADRB2_HUMAN |
Chronic obstructive pulmonary disease [ICD-11: CA22] |
P07550 |
ADRB2_HUMAN |
Conduction disorder [ICD-11: BC63] |
P07550 |
ADRB2_HUMAN |
Melanoma [ICD-11: 2C30] |
P07550 |
ADRB2_HUMAN |
Preterm labour/delivery [ICD-11: JB00] |
P07550 |
ADRB2_HUMAN |
Sleep-related breathing disorder [ICD-11: 7A4Z] |
P07550 |
ADRB2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P07550 |
ADRB2_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P07550 |
ADRB2_HUMAN |
Hypertension [ICD-11: BA00-BA04] |
P07550 |
ADRB2_HUMAN |
Supraventricular tachyarrhythmia [ICD-11: BC81] |
P07550 |
ADRB2_HUMAN |
Cachexia [ICD-11: MG20] |
P07550 |
ADRB2_HUMAN |
Dermal/subcutaneous connective tissue atrophy/degeneration [ICD-11: EE40] |
P07550 |
ADRB2_HUMAN |
Skin and skin-structure infection [ICD-11: 1F28-1G0Z] |
P07550 |
ADRB2_HUMAN |
Bladder disorder [ICD-11: GC01] |
P07550 |
ADRB2_HUMAN |
Obesity [ICD-11: 5B80-5B81] |
P07550 |
ADRB2_HUMAN |
Ejaculatory dysfunction [ICD-11: HA03] |
P07550 |
ADRB2_HUMAN |
Cardiovascular disease [ICD-11: BA00-BE2Z] |
Q96KQ7 |
EHMT2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q96KQ7 |
EHMT2_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
Q96KQ7 |
EHMT2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04637 |
P53_HUMAN |
Arterial occlusive disease [ICD-11: BD40] |
P04637 |
P53_HUMAN |
Lip/oral cavity/pharynx neoplasm [ICD-11: 2B6E] |
P04637 |
P53_HUMAN |
Metastatic liver/bile duct neoplasm [ICD-11: 2D80] |
P04637 |
P53_HUMAN |
Transplant rejection [ICD-11: NE84] |
P04637 |
P53_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P04637 |
P53_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P04637 |
P53_HUMAN |
Bladder cancer [ICD-11: 2C94] |
P04637 |
P53_HUMAN |
Brain cancer [ICD-11: 2A00] |
P04637 |
P53_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P04637 |
P53_HUMAN |
Esophageal cancer [ICD-11: 2B70] |
P04637 |
P53_HUMAN |
Head and neck cancer [ICD-11: 2D42] |
P04637 |
P53_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P04637 |
P53_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P04637 |
P53_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P04637 |
P53_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P04637 |
P53_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04637 |
P53_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P04637 |
P53_HUMAN |
Cervical cancer [ICD-11: 2C77] |
P04637 |
P53_HUMAN |
Endometrial cancer [ICD-11: 2C76] |
P04637 |
P53_HUMAN |
Fallopian tube cancer [ICD-11: 2C74] |
P04637 |
P53_HUMAN |
Liposarcoma [ICD-11: 2B59] |
P04637 |
P53_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P04637 |
P53_HUMAN |
Peritoneal cancer [ICD-11: 2C51] |
P04637 |
P53_HUMAN |
Toxicity [ICD-11: N.A.] |
P04637 |
P53_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04637 |
P53_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P04637 |
P53_HUMAN |
Kidney failure [ICD-11: GB60-GB6Z] |
P04637 |
P53_HUMAN |
Hearing disorder [ICD-11: AB50-AB57] |
P06280 |
AGAL_HUMAN |
Lysosomal disease [ICD-11: 5C56] |